Turner syndrome represents a condition that associates diverse pathology with somatic, metabolic (diabetes), cardio-vascular, digestive, respiratory and bone involvement along with chromosomal abnormalities. In our study we have analyzed the bone pathology that occurs in Turner syndrome and the response in the therapy with ibandronat. The decrease in value of the bone turn-over biomarkers and the decrease of the T score after the administration of ibandronate p.o. in a monthly dosage demonstrates the efficiency of this bisphosphonate in the treatment of the osteoporosis secondary to sexual hormone deficiency in Turner syndrome.